Morphic adds second integrin partnership with Janssen deal

Morphic Therapeutic (Waltham, Mass.) and Janssen Biotech Inc. partnered to discover and develop oral integrin therapies for undisclosed diseases not adequately addressed by current therapies. The multi-target collaboration will explore both inhibitors and activators of integrin function.

Morphic President and CEO Praveen Tipirneni told BioCentury the Johnson & Johnson (NYSE:JNJ) unit has already identified several integrin targets of interest; the collaboration will use Morphic's crystal structural integrin models to develop therapies...